Dr. Reddy's Laboratories Limited (RDY) trades at a trailing P/E of 17.8, forward P/E of 0.2. Trailing earnings yield is 5.61%, forward earnings yield 454.55%. PEG 0.04 (Peter Lynch undervalued ≤1.0). Graham Number is $830.71.
Criteria proven by this page:
Overall SharesGrow Score: 83/100 with 6/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 25.6 | -2.59 | 3.99 | 3.31 | 0.80% |
| 2017 | 36.0 | -0.94 | 3.50 | 3.08 | 0.78% |
| 2018 | 35.7 | -1.97 | 2.77 | 2.46 | 1.14% |
| 2019 | 24.9 | 0.27 | 3.33 | 3.04 | 0.86% |
| 2020 | 26.1 | 6.79 | 248.25 | 2.91 | 0.77% |
| 2021 | 3,220.8 | -39.12 | 315.97 | 292.64 | 0.55% |
| 2022 | 29.9 | 0.81 | 3.69 | 3.28 | 0.59% |
| 2023 | 17.2 | 0.19 | 3.36 | 3.16 | 0.64% |
| 2024 | 18.4 | 0.80 | 3.66 | 3.68 | 0.65% |
| 2025 | 16.6 | 10.58 | 2.82 | 2.89 | 0.71% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $23.40 | $154.71B | $20.01B | 12.9% |
| 2017 | $14.42 | $140.81B | $12.04B | 8.5% |
| 2018 | $11.80 | $142.03B | $9.81B | 6.9% |
| 2019 | $22.62 | $153.85B | $18.8B | 12.2% |
| 2020 | $23.48 | $174.6B | $19.5B | 11.2% |
| 2021 | $20.73 | $189.72B | $17.24B | 9.1% |
| 2022 | $28.34 | $214.39B | $23.57B | 11% |
| 2023 | $54.17 | $245.88B | $45.07B | 18.3% |
| 2024 | $66.80 | $279.16B | $55.68B | 19.9% |
| 2025 | $0.00 | $325.54B | $56.54B | 17.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $61.37 | $59.45 – $64.25 | $350.81B | $348.26B – $353.8B | 2 |
| 2027 | $55.64 | $52.81 – $62.25 | $363.12B | $361.48B – $417.49B | 2 |
| 2028 | $68.24 | $62.83 – $81.46 | $398.8B | $374.7B – $458.5B | 1 |
